Insights about U.S. Stocks from mix sectors that landed in the Green-Zone in the course of Tuesday’s trade, are depicted underneath:
Ally Financial Inc (NYSE:ALLY)’s shares picked up 4.16%, and closed at $21.01, during the last trading session, soon after the news release that Ally Financial Inc. formerly on February 25, declared the early results of its formerly declared modified “Dutch Auction” cash tender offers to purchase a portion of its outstanding (i) 2020 Notes with the maximum aggregate principal amount of 2020 Notes that Ally can accept in the 2020 Offer being up to $750,000,000 and (ii) the 2031 Notes, with the maximum aggregate principal amount of 2031 Notes that Ally can accept in the 2031 Offer being up to $150,000,000 (subject to raise, the “2031 Tender Cap” and, together with the 2020 Tender Cap, the “Tender Caps”). On Feb. 10, 2015, Ally commenced the Tender Offers in accordance with the terms and conditions described in an offer to purchase, dated Feb. 10, 2015, and a related Letter of Transmittal (collectively, the “Offer Documents”).
Ally also declared that it raised the maximum aggregate principal amount of the 2020 Offer from $750,000,000 to $800,000,000. This declaration amends the Offer Documents with respect to the 2020 Tender Cap. All other terms and conditions of the Tender Offers described in the Offer Documents remain unchanged.
Ally Financial Inc. provides financial products and services primarily to automotive dealers and their customers in the United States. It offers dealer financial services, counting a range of financial services and insurance products to automotive dealers and retail customers. The corporation also provides automotive finance services, such as new and used vehicle inventory financing; inventory insurance; term loans, counting real estate and working capital loans; and vehicle remarketing services, in addition to vehicle service contracts (VCSs) and guaranteed automobile protection (GAP) products.
Discovery Communications Inc (NASDAQ:DISCA), raised 4.12%, and closed at $33.99, soon after Discovery Communications, Inc. declared that it will report first quarter 2015 results on Tuesday, May 5, 2015, at 7:00 a.m. ET. The corporation will host a conference call at 8:30 a.m. ET to talk about the results.
To access the conference call in the U.S. dial 1-800-901-5213, or outside of the U.S. dial 1-617-786-2962, and use the following passcode: DISCA. Please dial in about 10 minutes in advance to ensure you are connected preceding to the starting of the call.
Discovery Communications, Inc. operates as a media corporation. The corporation operates through U.S. Networks; International Networks; and Education and Other segments. It owns and operates television networks under the brands, such as Discovery, TLC, Animal Planet, Investigation Discovery, Science, Velocity, Discovery Family, American Heroes, Destination America, Discovery Life, Oprah Winfrey network, Eurosport, DMAX, and Discovery Kids.
Threshold Pharmaceuticals, Inc (NASDAQ:THLD), enhanced 4.10%, and closed at $4.57, soon after the news release that Threshold Pharmaceuticals Inc. stated financial results for the fourth quarter and year ended December 31, 2014. Proceed for the fourth quarter and year ended December 31, 2014 was $3.7 million and $14.7 million, respectively. Net loss for the fourth quarter ended December 31, 2014 was $6.0 million, which comprised of the operating loss of $7.6 million and non-cash revenue of $1.6 million related to changes in the fair value of the Corporation’s outstanding and exercised warrants that was classified as other revenue (expense). Net loss for the year ended December 31, 2014 was $21.6 million, which comprised of the operating loss of $31.3 million and non-cash revenue of $9.3 million related to changes in the fair value of the Corporation’s outstanding and exercised warrants. As of December 31, 2014, Threshold had $58.6 million in cash, cash equivalents and marketable securities, with no debt outstanding. In February 2015, the Corporation accomplished an underwritten offering of Threshold ordinary stock and warrants. Net proceeds from the offering are predictable to be about $28.2 million.
Threshold Pharmaceuticals, Inc., a biotechnology corporation, discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the United States. Its lead investigational small molecule, TH-302, is being evaluated in two pivotal Phase III clinical trials for the treatment of soft tissue sarcoma indication and pancreatic cancer; and various earlier-stage clinical trials for therapeutic areas, counting advanced leukemias, multiple myeloma, advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors.
Capnia Inc (NASDAQ:CAPN), enhanced 17.00%, and closed at $7.50, soon after the news release that the company focused on the development of novel products based on its proprietary technologies for precision metering of gas flow, declared the first U.S. commercial sales of the Corporation’s CoSense End-Tidal Carbon Monoxide (ETCO) Monitors and single-use sampling sets to leading academic, research and healthcare institutions. CoSense is a portable, non-invasive device that rapidly and accurately measures carbon monoxide in exhaled breath. The measurement of carbon monoxide is the gold standard for measuring hemolysis, a condition that, if left untreated, may lead to elevated levels of bilirubin in the blood and a range of neuro-developmental disorders in newborns.
Of the 140 million babies born worldwide and 9.2 million babies born annually in the in the U.S. and European Union, more than 60% will present with jaundice at some point in the first five days of life. Jaundice is caused by the pigment bilirubin and may be a sign of excessive breakdown of red blood cells, or hemolysis. In infants, bilirubin is toxic to the brain and central nervous system. Exposure to high levels of bilirubin in newborns may lead to permanent neurological damage. These neurological abnormalities range from subtle ones such as learning disabilities and impaired hearing to severe life threatening outcomes such as acute bilirubin encephalopathy, or a chronic disabling disease called kernicterus.
The American Academy of Pediatrics guidelines state that ETCO monitoring is the only clinical test that provides a direct measurement of the rate of bilirubin production, and therefore hemolysis. The guidelines recommend ETCO measurement be performed to assess the presence of hemolysis in neonates in several clinical circumstances. CoSense is the only accessible device to accurately measure the ETCO levels in neonates and therefore the only device that enables physicians to practice in accordance with the AAP guidelines when evaluating jaundiced neonates for potential treatment.
Capnia, Inc. develops and commercializes therapeutics and diagnostics products. The corporation offers CoSense for the diagnosis of excessive hemolysis in neonates, a condition that causes long-term developmental disability due to degradation of red blood cells. It also develops Serenz, a therapeutic product candidate that has accomplished Phase II clinical trials for the treatment of symptoms related to allergic rhinitis. The corporation was founded in 1999 and is based in Redwood City, California.
